{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:55:40Z","timestamp":1789498540772,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02455-8","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T02:02:55Z","timestamp":1678500175000},"page":"2249-2264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6606-4507","authenticated-orcid":false,"given":"Delbert G.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Chaijale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaine","family":"Cloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Mychaskiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"2","key":"2455_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360. https:\/\/doi.org\/10.1002\/wps.20516.","journal-title":"World Psychiatry"},{"issue":"9","key":"2455_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-017-0515-3","volume":"35","author":"M Pennington","year":"2017","unstructured":"Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921\u201336. https:\/\/doi.org\/10.1007\/s40273-017-0515-3.","journal-title":"Pharmacoeconomics"},{"key":"2455_CR3","doi-asserted-by":"publisher","unstructured":"Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036\u201342. https:\/\/doi.org\/10.1038\/s41386-018-0278-3.","DOI":"10.1038\/s41386-018-0278-3"},{"issue":"6","key":"2455_CR4","doi-asserted-by":"publisher","first-page":"e0179425","DOI":"10.1371\/journal.pone.0179425","volume":"12","author":"Y Yu","year":"2017","unstructured":"Yu Y, Liu ZW, Tang BW, Zhao M, Liu XG, Xiao SY. Reported family burden of schizophrenia patients in rural China. PLoS ONE. 2017;12(6):e0179425. https:\/\/doi.org\/10.1371\/journal.pone.0179425.","journal-title":"PLoS ONE"},{"issue":"10","key":"2455_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/jcp.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909. https:\/\/doi.org\/10.4088\/jcp.v63n1007.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2455_CR6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.18553\/jmcp.2016.22.11.1349","volume":"22","author":"JP MacEwan","year":"2016","unstructured":"MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1349\u201361. https:\/\/doi.org\/10.18553\/jmcp.2016.22.11.1349.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2455_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326. https:\/\/doi.org\/10.1002\/wps.20060.","journal-title":"World Psychiatry"},{"key":"2455_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/ppa.s3346","volume":"2","author":"M Birnbaum","year":"2008","unstructured":"Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence. 2008;2:233\u201340. https:\/\/doi.org\/10.2147\/ppa.s3346.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"2455_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4088\/jcp.v69n0512","volume":"69","author":"J Lauriello","year":"2008","unstructured":"Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790\u20139. https:\/\/doi.org\/10.4088\/jcp.v69n0512.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2455_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","volume":"25","author":"D Najarian","year":"2021","unstructured":"Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2021;25(3):238\u201351. https:\/\/doi.org\/10.1093\/ijnp\/pyab071.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"2455_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4088\/JCP.14m09168","volume":"75","author":"JM Kane","year":"2014","unstructured":"Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254\u201360. https:\/\/doi.org\/10.4088\/JCP.14m09168.","journal-title":"J Clin Psychiatry"},{"key":"2455_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.schres.2018.07.020","volume":"202","author":"RE Nielsen","year":"2018","unstructured":"Nielsen RE, Hessellund KB, Valentin JB, Licht RW. Second-generation LAI are associated to favorable outcome in a cohort of incident patients diagnosed with schizophrenia. Schizophr Res. 2018;202:234\u201340. https:\/\/doi.org\/10.1016\/j.schres.2018.07.020.","journal-title":"Schizophr Res"},{"issue":"8","key":"2455_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0270.","journal-title":"JAMA Psychiat"},{"issue":"2\u20133","key":"2455_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2\u20133):220\u201330. https:\/\/doi.org\/10.1016\/j.schres.2016.07.018.","journal-title":"Schizophr Res"},{"issue":"5","key":"2455_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404. https:\/\/doi.org\/10.1016\/S2215-0366(21)00039-0.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"2455_CR16","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.clinthera.2008.12.020","volume":"30","author":"R Emsley","year":"2008","unstructured":"Emsley R, Oosthuizen P, Koen L, Niehaus DJH, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378\u201386. https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.020.","journal-title":"Clin Ther"},{"issue":"5","key":"2455_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","volume":"178","author":"G Ostuzzi","year":"2021","unstructured":"Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):424\u201336. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20071120.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"2455_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","volume":"77","author":"JM Kane","year":"2020","unstructured":"Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(12):1217\u201324. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2076.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"2455_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1176\/appi.ps.201900236","volume":"71","author":"DG Robinson","year":"2020","unstructured":"Robinson DG, Subramaniam A, Fearis PJ, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv. 2020;71(4):337\u201342. https:\/\/doi.org\/10.1176\/appi.ps.201900236.","journal-title":"Psychiatr Serv"},{"key":"2455_CR20","doi-asserted-by":"publisher","unstructured":"Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019;80(3):18m12546. https:\/\/doi.org\/10.4088\/JCP.18m12546.","DOI":"10.4088\/JCP.18m12546"},{"issue":"5 Suppl 1","key":"2455_CR21","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1177\/088740341305805s04","volume":"58","author":"S Iyer","year":"2013","unstructured":"Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):S23\u2013S29. https:\/\/doi.org\/10.1177\/088740341305805s04.","journal-title":"Can J Psychiatry"},{"issue":"10","key":"2455_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1177\/0269881109104882","volume":"24","author":"MX Patel","year":"2010","unstructured":"Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists\u2019 use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24(10):1473\u201382. https:\/\/doi.org\/10.1177\/0269881109104882.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2455_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","volume":"20","author":"MX Patel","year":"2020","unstructured":"Patel MX, Bent-Ennakhil N, Sapin C, et al. Attitudes of European physicians towards the use of long-acting injectable antipsychotics. BMC Psychiatry. 2020;20(1):123. https:\/\/doi.org\/10.1186\/s12888-020-02530-2.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"2455_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378. https:\/\/doi.org\/10.3109\/15622975.2012.696143.","journal-title":"World J Biol Psychiatry"},{"key":"2455_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-0500-2-6","volume":"2","author":"H Ascher-Svanum","year":"2009","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:6. https:\/\/doi.org\/10.1186\/1756-0500-2-6.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2455_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359. https:\/\/doi.org\/10.1007\/s40263-020-00779-5.","journal-title":"CNS Drugs"},{"issue":"1","key":"2455_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41537-020-00127-y","volume":"6","author":"CU Correll","year":"2020","unstructured":"Correll CU, Litman RE, Filts Y, et al. Efficacy and safety of once-monthly Risperidone ISM\u00ae in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37. https:\/\/doi.org\/10.1038\/s41537-020-00127-y.","journal-title":"NPJ Schizophr"},{"key":"2455_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/NDT.S326299","volume":"18","author":"L Citrome","year":"2022","unstructured":"Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians [published correction appears in Schizophrenia]. Neuropsychiatr Dis Treat. 2022;18:111\u201323. https:\/\/doi.org\/10.2147\/NDT.S326299.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2455_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S251812","volume":"14","author":"C Blackwood","year":"2020","unstructured":"Blackwood C, Sanga P, Nuamah I, et al. Patients\u2019 preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire. Patient Prefer Adherence. 2020;14:1093\u2013102. https:\/\/doi.org\/10.2147\/PPA.S251812.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"2455_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1369-7625.2011.00704.x","volume":"16","author":"JFP Bridges","year":"2013","unstructured":"Bridges JFP, Slawik L, Schmeding A, Reimer J, Naber D, Kuhnigk O. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect. 2013;16(2):164\u201376. https:\/\/doi.org\/10.1111\/j.1369-7625.2011.00704.x.","journal-title":"Health Expect"},{"key":"2455_CR31","doi-asserted-by":"crossref","unstructured":"McCrone P, Mosweu I, Yi D, Ruffell T, Dalton B, Wykes T. Patient preferences for antipsychotic drug side effects: a discrete choice experiment. Schizophrenia Bull Open. 2021;2(1):sgab046.","DOI":"10.1093\/schizbullopen\/sgab046"},{"issue":"1","key":"2455_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","volume":"18","author":"E Achtyes","year":"2018","unstructured":"Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18(1):292. https:\/\/doi.org\/10.1186\/s12888-018-1856-y.","journal-title":"BMC Psychiatry"},{"issue":"7","key":"2455_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/appi.ps.201400188","volume":"66","author":"B Levitan","year":"2015","unstructured":"Levitan B, Markowitz M, Mohamed AF, et al. Patients\u2019 preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719. https:\/\/doi.org\/10.1176\/appi.ps.201400188.","journal-title":"Psychiatr Serv"},{"key":"2455_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/PPA.S187120","volume":"13","author":"DL Gandell","year":"2019","unstructured":"Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18\u201345 years old. Patient Prefer Adherence. 2019;13:351\u201361. https:\/\/doi.org\/10.2147\/PPA.S187120.","journal-title":"Patient Prefer Adherence"},{"key":"2455_CR35","doi-asserted-by":"publisher","first-page":"531763","DOI":"10.3389\/fnins.2020.531763","volume":"14","author":"K El Abdellati","year":"2020","unstructured":"El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis. Front Neurosci. 2020;14:531763. https:\/\/doi.org\/10.3389\/fnins.2020.531763.","journal-title":"Front Neurosci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02455-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:12:32Z","timestamp":1682435552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02455-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02455-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}